The Hagedorn Prize is an annual award within the field of medical research, specifically recognizing outstanding contributions to diabetes research and endocrinology. Named after Hans Christian Hagedorn, a renowned Danish scientist and co-founder of Nordisk Insulinlaboratorium [1] (now part of Novo Nordisk), the prize celebrates achievements in the understanding and treatment of diabetes. [2]
Hagedorn's work significantly advanced the quality of insulin production and diabetes care, making this award a tribute to his legacy in the field. The Hagedorn Prize is recognised as the most prestigious award in Internal medicine in Denmark. [3]
The Hagedorn Prize was established by the Danish Society of Internal Medicine in 1966 to recognize the contribution to medical science made by Hans Christian Hagedorn (1888–1971). [4] The prize is awarded at the society's annual general meeting. [5]
Initially, the Hagedorn Prize received its endowment from a distinct foundation, funded by contributions from Nordisk Insulinlaboratorium, with the Board of the Danish Society for Internal Medicine serving as its governing body. However, by 2008, the foundation's resources were deemed inadequate to sustain a meaningful award. Consequently, the remaining capital was transferred to the Novo Nordisk Foundation, which subsequently assumed the responsibility of bestowing the Hagedorn Prize, while maintaining the ongoing involvement of the Society. The recipient of the prize is determined by the society's board, relying on recommendations provided by its members. [5]
The Danish Society of Internal Medicine, comprising nearly 4,500 members, serves as an overarching body for the nine internal medicine specialties within Denmark. Its objectives include the advancement of scientific research in internal medicine and the facilitation of ongoing education for specialist physicians in the discipline. Established in 1916, the Society operates with a board of directors composed of nine members, appointed by the boards of each respective internal medicine specialty. [6]
The Hagedorn Prize includes a monetary component, designed to support the ongoing research of the recipient. In addition, awardees are presented with a medal and a certificate recognizing their contributions to advancing diabetes research and treatment. The prize is intended not only to honor individuals for their past achievements but also to encourage further innovation and research in diabetes care. [5]
List of recipients of The Hagedorn Prize [7]
Year | Recipient | Year | Recipient | Year | Recipient |
---|---|---|---|---|---|
2023 | Else Marie Skjøde Damsgaard | 2002 | Hans Henrik Parving | 1983 | Povl Riis |
2022 | Jens Bukh [8] | 2001 | Hans Ibsen | 1982 | Niels Tygstrup |
2021 | Hans Carl Hasselbalch | 2000 | Ove B. Schaffalitzky | 1981 | Niels Juel Christensen |
2020 | Michael Kjær | 1999 | Hans Ørskov | 1980 | Kurt Iversen |
2019 | Hans Erik Bøtker | 1998 | Jens Kampmann | 1979 | Henrik R. Wulff |
2018 | Asbjørn Mohr Drewes | 1997 | Jørgen Fischer Hansen | 1978 | Knud Olesen |
2017 | Jens Dilling Lundgren | 1996 | Vagn Andersen | 1977 | Ib Lorenzen |
2016 | Jørgen Vestbo | 1995 | Niels Ebbe Hansen | 1976 | Jørgen Hess Thaysen |
2015 | Oluf Borbye Pedersen | 1994 | Vibeke Binder | 1975 | Jørgen Pedersen |
2014 | Bo Feldt-Rasmussen | 1993 | Anders Frøland | 1974 | Stig Jarnum |
2013 | Lars Køber | 1992 | Jens Mølholm | 1973 | Mogens Bjørneboe |
2012 | Henrik Toft Sørensen | 1991 | Tage Astrup | 1972 | Knud Lundbæk |
2011 | Ulla Feldt-Rasmussen | 1991 | Allan Erslev | 1971 | Svend-Aage Kiilman |
2010 | Torsten Toftegaard Nielsen | 1990 | Leif Mosekilde | 1970 | Viggo Faber |
2009 | Sten Madsbad | 1989 | Thorkild I. A. Sørensen | 1970 | Gunnar Bendixen |
2008 | Gorm Boje Jensen | 1989 | Marianne Schroll | 1969 | Michael Schwartz |
2007 | Hendrik Vilstrup | 1988 | Carl Erik Mogensen | 1968 | Villy Posborg Petersen |
2006 | Allan Flyvbjerg | 1987 | Bent Harvald | 1967 | Laurids Korsgaard Christensen |
2005 | Henning Beck-Nielsen | 1986 | Halfdan Mahler | 1966 | Tage Hilden |
2004 | Bente Klarlund Pedersen | 1985 | Kresten Mellemgaard | ||
2003 | Heine Høi Hansen | 1984 | Jørn Nerup |
John James Rickard Macleod,, was a Scottish biochemist and physiologist. He devoted his career to diverse topics in physiology and biochemistry, but was chiefly interested in carbohydrate metabolism. He is noted for his role in the discovery and isolation of insulin during his tenure as a lecturer at the University of Toronto, for which he and Frederick Banting received the 1923 Nobel prize in Physiology or Medicine.
Bernardo Alberto Houssay was an Argentine physiologist. Houssay was a co-recipient of the 1947 Nobel Prize for Physiology or Medicine for discovering the role played by pituitary hormones in regulating the amount of glucose in animals, sharing the prize with Carl Ferdinand Cori and Gerty Cori. He is the first Latin American Nobel laureate in the sciences.
Schack August Steenberg Krogh was a Danish professor at the department of zoophysiology at the University of Copenhagen from 1916 to 1945. He contributed a number of fundamental discoveries within several fields of physiology, and is famous for developing the Krogh Principle.
Rosalyn Sussman Yalow was an American medical physicist, and a co-winner of the 1977 Nobel Prize in Physiology or Medicine for development of the radioimmunoassay technique. She was the second woman, and the first American-born woman, to be awarded the Nobel Prize in Physiology or Medicine.
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd with production facilities in nine countries and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28% of its shares and a majority (77%) of its voting shares.
An insulin analog is any of several types of medical insulin that are altered forms of the hormone insulin, different from any occurring in nature, but still available to the human body for performing the same action as human insulin in terms of controlling blood glucose levels in diabetes. Through genetic engineering of the underlying DNA, the amino acid sequence of insulin can be changed to alter its ADME characteristics. Officially, the U.S. Food and Drug Administration (FDA) refers to these agents as insulin receptor ligands, although they are usually just referred to as insulin analogs or even just insulin.
Neutral Protamine Hagedorn (NPH) insulin, also known as isophane insulin, is an intermediate-acting insulin given to help control blood sugar levels in people with diabetes. It is used by injection under the skin once to twice a day. Onset of effects is typically in 90 minutes and they last for 24 hours. Versions are available that come premixed with a short-acting insulin, such as regular insulin.
Matthias Mann is a German physicist and biochemist. He is doing research in the area of mass spectrometry and proteomics.
Hans Christian Jacobaeus was a Swedish internist born in Skarhult.
Hans Christian Hagedorn was the creator of NPH insulin and the founder of Nordisk Insulinlaboratorium, which is known today as Novo Nordisk.
Mark Atkinson is an American medical researcher best known for his contributions to research seeking to predict, prevent, and cure type 1 diabetes. He is the author of over 600 publications and is one of the world's most cited diabetes researchers.
Carl Ronald Kahn is an American physician and scientist, best known for his work with insulin receptors and insulin resistance in diabetes and obesity. He is the Chief Academic Officer at Joslin Diabetes Center, the Mary K. Iacocca Professor of Medicine at Harvard Medical School and a member of the National Academy of Sciences since 1999.
The Novo Nordisk Foundation is an international enterprise foundation focusing on medical treatment and research.
Gökhan S. Hotamisligil is a Turkish-American physician scientist; James Stevens Simmons Chair of Genetics and Metabolism at Harvard T.H. Chan School of Public Health (HSPH); Director of the Sabri Ülker Center for Metabolic Research and associate member of Harvard-MIT Broad Institute, Harvard Stem Cell Institute and the Joslin Diabetes Center.
Avideh Nazeri is an Iranian endocrinologist who is director of clinical, medical, and regulatory for Novo Nordisk UK and Ireland.
Drew Weissman is an American physician and immunologist known for his contributions to RNA biology. Weissman is the inaugural Roberts Family Professor in Vaccine Research, director of the Penn Institute for RNA Innovation, and professor of medicine at the Perelman School of Medicine at the University of Pennsylvania (Penn).
Mads Krogsgaard Thomsen is a Danish businessman, CEO of the Novo Nordisk Foundation and former Executive Vice President of Research & Development, head of R&D and Chief Scientific Officer (CSO) at the pharmaceutical company Novo Nordisk.
The Novo Nordisk Prize is an annual award presented to acknowledge exceptional contributions within the fields of medical and health sciences. It is specifically aimed at individuals who have demonstrated outstanding research or innovation that has the potential to advance medical science, particularly in areas related to diabetes, endocrinology, and biopharmaceutical science. The prize is administered by the Novo Nordisk Foundation, an independent Danish foundation with a broad commitment to scientific research and humanitarian objectives.
The Novozymes Prize is an annual scientific award. The prize aims to recognise outstanding contributions to the advancement of science within the fields of biotechnology and bioinnovation.
The Jacobaeus Prize, (also known as the "Jacobæus Prize") is regarded as a prestigious recognition within the field of medical research. It is an annual award given to individuals who have made significant contributions to the advancement of medical science, particularly in the areas of physiology or endocrinology.